Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells

• Váldodahkkit: Emily M. Esquea (Dahkki), Lorela Ciraku (Dahkki), Riley G. Young (Dahkki), Jessica Merzy (Dahkki), Alexandra N. Talarico (Dahkki), Nusaiba N. Ahmed (Dahkki), Mangalam Karuppiah (Dahkki), Anna Ramesh (Dahkki), Adam Chatoff (Dahkki), Claudia V. Crispim (Dahkki), Adel A. Rashad (Dahkki), Simon Cocklin (Dahkki), Nathaniel W. Snyder (Dahkki), Joris Beld (Dahkki), Nicole L. Simone (Dahkki), Mauricio J. Reginato (Dahkki), Alexej Dick (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Breast cancer brain metastasis (BCBM) typically results in an end-stage diagnosis and is hindered by a lack of brain-penetrant drugs. Tumors in the brain rely on the conversion of acetate to acetyl-CoA by the enzyme acetyl-CoA synthetase 2 (ACSS2), a key regulator of fatty acid synthesis and protein...